Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Federal Circuit Rules In Favor Of Reddy’s Again On Vimovo

Indian Firm Launched In February 2020

Executive Summary

Dr Reddy’s Laboratories has once again prevailed over Horizon Pharma and Nuvo in litigation over patents shielding the originators’ Vimovo, with the US Court of Appeals for the Federal Circuit affirming a lower court's invalidity ruling.

You may also be interested in...



Dr Reddy’s Debuts US Vimovo Rival At Risk

Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.

Reddy’s, Lupin And Mylan Clear Two Vimovo Patents From Path

Three generics players in the US have helped to clear the path for generic rivals to the Vimovo analgesic by winning an appeals verdict of written descriptions for two patents.

Reddy’s and Mylan beat Vimovo

Two US method-of-treatment patents protecting Horizon Pharma’s Vimovo (naproxen/esomeprazole) delayed-release tablets up to 2031 are invalid on the ground of indefiniteness, Dr Reddy’s and Mylan have convinced New Jersey District Judge Stanley Chesler.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel